Alan J Sinclair

TL;DR: This guideline is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.

TL;DR: There is a need for more data from national and regional sources on those aged 65 years and over but the prevailing evidence points to diabetes being a considerable global chronic illness burden in ageing societies.

TL;DR: A conceptual framework for approaching screening and diagnosis of cognitive impairment and dementia in those with type 2 diabetes, management of diabetes in people with cognitive dysfunction, and emerging therapies for prevention are included.

TL;DR: The International Conference on Frailty and Sarcopenia Research Task Force met in April 2017 to discuss the meaning, significance, and barriers to the implementation of the new code for sarcopenia as well as strategies to accelerate development of new therapies.

TL;DR: The lack of a consensus definition for sarcopenia and frailty was felt as still present and severely limiting advancements in the field, however, agreement appears to be emerging that low mass alone provides insufficient clinical relevance if not combined with muscle weakness and/or functional impairment.